Today Osmotica Pharmaceuticals plc (OSMT) Stock Reaches All-Time Low

The stock of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) reached all time low today, May, 8 and still has $3.36 target or 5.00 % below today’s $3.53 share price. This indicates more downside for the $185.58 million company. This technical setup was reported by Barchart.com. If the $3.36 PT is reached, the company will be worth $9.28M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 7.98% or $0.3064 during the last trading session, reaching $3.5336. About 477,480 shares traded or 312.07% up from the average. Osmotica Pharmaceuticals plc (NASDAQ:OSMT) has 0.00% since May 8, 2018 and is . It has underperformed by 4.37% the S&P500.

Analysts await Osmotica Pharmaceuticals plc (NASDAQ:OSMT) to report earnings on May, 9 after the close.

More notable recent Osmotica Pharmaceuticals plc (NASDAQ:OSMT) news were published by: Seekingalpha.com which released: “Stocks To Watch: Apple Makes Its Video-Streaming Move – Seeking Alpha” on March 23, 2019, also Nasdaq.com with their article: “Osmotica Pharmaceuticals files for a $100 million IPO – Nasdaq” published on September 14, 2018, Seekingalpha.com published: “Adamas Knife Continues To Fall As Value Continues To Rise – Seeking Alpha” on December 26, 2018. More interesting news about Osmotica Pharmaceuticals plc (NASDAQ:OSMT) were released by: Nasdaq.com and their article: “Extended release drug maker Osmotica Pharmaceuticals decreases proposed IPO deal size – Nasdaq” published on October 17, 2018 as well as Benzinga.com‘s news article titled: “31 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” with publication date: May 07, 2019.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, makes, and commercializes specialty products that target markets with underserved patient populations. The company has market cap of $185.58 million. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. It currently has negative earnings. The Company’s non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.